Commenting ahead of the Gavi pledging conference that is expected to raise at least US$ 7.4 billion to support the roll out of vaccination programmes across the developing globe, and establish a new fund to help poor countries buy and distribute a coronavirus vaccine, Anna Marriott, Oxfam’s Health Policy Manager said:
“Oxfam welcomes the funds to support Gavi’s ongoing work helping to protect the world’s poorest children against diseases such as pneumonia.
“The establishment of a new fund to help developing countries pay for a coronavirus vaccine is a step forward. However, Gavi, and the governments that fund it, should first confront the monopoly power of the pharmaceutical industry that is standing in the way of a People’s Vaccine. Taxpayers’ money should be invested in vaccines and treatments that are patent free and available to all nations at cost price – not used to line the pockets of wealthy pharmaceutical companies.”